Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Net Income towards Common Stockholders (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Net Income towards Common Stockholders for 3 consecutive years, with -$4.0 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Net Income towards Common Stockholders fell 130.17% year-over-year to -$4.0 million, compared with a TTM value of -$12.9 million through Dec 2024, down 557.01%, and an annual FY2024 reading of -$16.8 million, down 430.52% over the prior year.
  • Net Income towards Common Stockholders was -$4.0 million for Q4 2024 at Oramed Pharmaceuticals, up from -$19.6 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $13.3 million in Q4 2023 and bottomed at -$19.6 million in Q3 2024.
  • Average Net Income towards Common Stockholders over 3 years is -$4.1 million, with a median of -$3.9 million recorded in 2023.
  • Peak annual rise in Net Income towards Common Stockholders hit 342.79% in 2024, while the deepest fall reached 498.11% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at -$11.7 million in 2022, then skyrocketed by 213.95% to $13.3 million in 2023, then tumbled by 130.17% to -$4.0 million in 2024.
  • Business Quant data shows Net Income towards Common Stockholders for ORMP at -$4.0 million in Q4 2024, -$19.6 million in Q3 2024, and $9.2 million in Q2 2024.